In December 2024, Western Europe’s PV selling rate continued its upward trend, reaching 13.1 million units/year. Year-on-year ...

Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

A ccording to preliminary estimates, Light Vehicle (LV) sales grew by 2.4% year-on-year (YoY) in December, to 1.51 million ...

This reflects the Asian nations’ “commitment to bolstering its petrochemical sector, positioning it for sustained dominance ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

In recent years, the oil and gas industry has progressed from using digital technologies for select use cases to making their ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully ...

Novartis has announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) achieved the primary ...